Home Latest News News Der Botenstoff TNF: Freund oder Feind? Das hängt von seiner zellulären Herkunft ab!
Research ticker |

Contrasting contributions of TNF from distinct cellular sources in arthritis

Anti-tumour necrosis factor (TNF) therapy is widely used as a treatment for rheumatoid arthritis (RA). However, Andrey Kruglov and Sergei Nedospasov from DRFZ have found deleterious and protective TNF functions in arthritis to distinct cellular sources and molecular forms. TNF produced by myeloid cells controls arthritis induction through regulation of synovial fibroblast activation, while B cell-derived TNF regulates severity via induction of autoantibodies. Instead, TNF produced by T cells limits arthritis development via control of T cell responses during induction phase of arthritis but is dispensable for the pathogenesis. Thus a cell type-specific TNF blockade for patients with RA may be superior to pan-anti-TNF therapy.

Full text publication
Kruglov A, Drutskaya M, Schlienz D, Gorshkova E, Kurz K, Morawietz L, Nedospasov S. Contrasting contributions of TNF from distinct cellular sources in arthritis. Ann Rheum Dis. 2020 Aug 12:annrheumdis-2019-216068. doi: 10.1136/annrheumdis-2019-216068. Epub ahead of print. PMID: 32796044.
Chronic inflammation Dr. Andrey Kruglov Phone +49 (0)30 28460-641/643 kruglov@drfz.de more
Sign up for the
DRFZ NewsFlash